Barclays’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-3,018
| Closed | -$1K | – | 5580 |
|
|
2022
Q3 | $1K | Hold |
3,018
| – | – | ﹤0.01% | 4737 |
|
|
2022
Q2 | $1K | Sell |
3,018
-5,525
| -65% | -$2.79K | ﹤0.01% | 4979 |
|
|
2022
Q1 | $6K | Sell |
8,543
-6,313
| -42% | -$6.93K | ﹤0.01% | 4691 |
|
|
2021
Q4 | $34K | Sell |
14,856
-2,561
| -15% | -$8.66K | ﹤0.01% | 3894 |
|
|
2021
Q3 | $80K | Sell |
17,417
-1,593
| -8% | -$7.01K | ﹤0.01% | 3988 |
|
|
2021
Q2 | $84K | Sell |
19,010
-9,557
| -33% | -$48.6K | ﹤0.01% | 3917 |
|
|
2021
Q1 | $208K | Buy |
28,567
+8,417
| +42% | +$69.3K | ﹤0.01% | 3691 |
|
|
2020
Q4 | $154K | Buy |
20,150
+11,656
| +137% | +$78K | ﹤0.01% | 3916 |
|
|
2020
Q3 | $77K | Buy |
8,494
+1,888
| +29% | +$14.3K | ﹤0.01% | 4383 |
|
|
2020
Q2 | $56K | Buy |
6,606
+3,877
| +142% | +$25.5K | ﹤0.01% | 4878 |
|
|
2020
Q1 | $14K | Sell |
2,729
-5,573
| -67% | -$43.3K | ﹤0.01% | 5737 |
|
|
2019
Q4 | $60K | Buy |
8,302
+4,254
| +105% | +$38.4K | ﹤0.01% | 5689 |
|
|
2019
Q3 | $44K | Sell |
4,048
-1,343
| -25% | -$14.4K | ﹤0.01% | 5973 |
|
|
2019
Q2 | $70K | Buy |
5,391
+3,176
| +143% | +$42.2K | ﹤0.01% | 5929 |
|
|
2019
Q1 | $22K | Buy |
2,215
+217
| +11% | +$2.02K | ﹤0.01% | 6334 |
|
|
2018
Q4 | $21K | Buy |
+1,998
| New | +$24.1K | ﹤0.01% | 5884 |
|
Barclays's LOGC Position: Q4 2022 in Review
Barclays sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 3,018 shares — an estimated $1K sold.
Barclays first reported a position in LOGC in Q4 2018 and held it in 16 quarters. The position peaked at $208K in Q1 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.
- Barclays reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- Barclays sold 3,018 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $1K.
- Barclays first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 16 quarters.
- Barclays's LogicBio Therapeutics, Inc. Common Stock position peaked at $208K in Q1 2021.
- 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.
Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.